The mutation-associated neoantigen functional expansion of specific T cells (MANAFEST) assay: A sensitive platform for monitoring antitumor immunity

Liudmila V Danilova, Valsamo Anagnostou, Justina X. Caushi, John William Sidhom, Haidan Guo, Hok Yee Chan, Prerna Suri, Ada Tam, Jiajia Zhang, Margueritta El Asmar, Kristen Marrone, Jarushka Naidoo, Julie Brahmer, Patrick Forde, Alexander Baras, Leslie Cope, Victor E Velculescu, Andrew Mark Pardoll, Franck Housseau, Kellie Smith

Research output: Contribution to journalArticle

Abstract

Mutation-associated neoantigens (MANA) are a target of antitumor T-cell immunity. Sensitive, simple, and standardized assays are needed to assess the repertoire of functional MANA-specific T cells in oncology. Assays analyzing in vitro cytokine production such as ELISpot and intracellular cytokine staining have been useful but have limited sensitivity in assessing tumor-specific T-cell responses and do not analyze antigen-specific T-cell repertoires. The FEST (Functional Expansion of Specific T cells) assay described herein integrates T-cell receptor sequencing of short-term, peptide-stimulated cultures with a bioinformatic platform to identify antigen-specific clonotypic amplifications. This assay can be adapted for all types of antigens, including MANAs via tumor exome-guided prediction of MANAs. Following in vitro identification by the MANAFEST assay, the MANA-specific CDR3 sequence can be used as a molecular barcode to detect and monitor the dynamics of these clonotypes in blood, tumor, and normal tissue of patients receiving immunotherapy. MANAFEST is compatible with high-throughput routine clinical and lab practices.

Original languageEnglish (US)
Pages (from-to)888-899
Number of pages12
JournalCancer immunology research
Volume6
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Immunity
T-Lymphocytes
Mutation
Antigens
Cytokines
Exome
Neoplasms
T-Cell Antigen Receptor
Computational Biology
Immunotherapy
Staining and Labeling
Peptides

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

The mutation-associated neoantigen functional expansion of specific T cells (MANAFEST) assay : A sensitive platform for monitoring antitumor immunity. / Danilova, Liudmila V; Anagnostou, Valsamo; Caushi, Justina X.; Sidhom, John William; Guo, Haidan; Chan, Hok Yee; Suri, Prerna; Tam, Ada; Zhang, Jiajia; Asmar, Margueritta El; Marrone, Kristen; Naidoo, Jarushka; Brahmer, Julie; Forde, Patrick; Baras, Alexander; Cope, Leslie; Velculescu, Victor E; Pardoll, Andrew Mark; Housseau, Franck; Smith, Kellie.

In: Cancer immunology research, Vol. 6, No. 8, 01.08.2018, p. 888-899.

Research output: Contribution to journalArticle

@article{71069bdd17be4efb9564be528ff219dd,
title = "The mutation-associated neoantigen functional expansion of specific T cells (MANAFEST) assay: A sensitive platform for monitoring antitumor immunity",
abstract = "Mutation-associated neoantigens (MANA) are a target of antitumor T-cell immunity. Sensitive, simple, and standardized assays are needed to assess the repertoire of functional MANA-specific T cells in oncology. Assays analyzing in vitro cytokine production such as ELISpot and intracellular cytokine staining have been useful but have limited sensitivity in assessing tumor-specific T-cell responses and do not analyze antigen-specific T-cell repertoires. The FEST (Functional Expansion of Specific T cells) assay described herein integrates T-cell receptor sequencing of short-term, peptide-stimulated cultures with a bioinformatic platform to identify antigen-specific clonotypic amplifications. This assay can be adapted for all types of antigens, including MANAs via tumor exome-guided prediction of MANAs. Following in vitro identification by the MANAFEST assay, the MANA-specific CDR3 sequence can be used as a molecular barcode to detect and monitor the dynamics of these clonotypes in blood, tumor, and normal tissue of patients receiving immunotherapy. MANAFEST is compatible with high-throughput routine clinical and lab practices.",
author = "Danilova, {Liudmila V} and Valsamo Anagnostou and Caushi, {Justina X.} and Sidhom, {John William} and Haidan Guo and Chan, {Hok Yee} and Prerna Suri and Ada Tam and Jiajia Zhang and Asmar, {Margueritta El} and Kristen Marrone and Jarushka Naidoo and Julie Brahmer and Patrick Forde and Alexander Baras and Leslie Cope and Velculescu, {Victor E} and Pardoll, {Andrew Mark} and Franck Housseau and Kellie Smith",
year = "2018",
month = "8",
day = "1",
doi = "10.1158/2326-6066.CIR-18-0129",
language = "English (US)",
volume = "6",
pages = "888--899",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - The mutation-associated neoantigen functional expansion of specific T cells (MANAFEST) assay

T2 - A sensitive platform for monitoring antitumor immunity

AU - Danilova, Liudmila V

AU - Anagnostou, Valsamo

AU - Caushi, Justina X.

AU - Sidhom, John William

AU - Guo, Haidan

AU - Chan, Hok Yee

AU - Suri, Prerna

AU - Tam, Ada

AU - Zhang, Jiajia

AU - Asmar, Margueritta El

AU - Marrone, Kristen

AU - Naidoo, Jarushka

AU - Brahmer, Julie

AU - Forde, Patrick

AU - Baras, Alexander

AU - Cope, Leslie

AU - Velculescu, Victor E

AU - Pardoll, Andrew Mark

AU - Housseau, Franck

AU - Smith, Kellie

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Mutation-associated neoantigens (MANA) are a target of antitumor T-cell immunity. Sensitive, simple, and standardized assays are needed to assess the repertoire of functional MANA-specific T cells in oncology. Assays analyzing in vitro cytokine production such as ELISpot and intracellular cytokine staining have been useful but have limited sensitivity in assessing tumor-specific T-cell responses and do not analyze antigen-specific T-cell repertoires. The FEST (Functional Expansion of Specific T cells) assay described herein integrates T-cell receptor sequencing of short-term, peptide-stimulated cultures with a bioinformatic platform to identify antigen-specific clonotypic amplifications. This assay can be adapted for all types of antigens, including MANAs via tumor exome-guided prediction of MANAs. Following in vitro identification by the MANAFEST assay, the MANA-specific CDR3 sequence can be used as a molecular barcode to detect and monitor the dynamics of these clonotypes in blood, tumor, and normal tissue of patients receiving immunotherapy. MANAFEST is compatible with high-throughput routine clinical and lab practices.

AB - Mutation-associated neoantigens (MANA) are a target of antitumor T-cell immunity. Sensitive, simple, and standardized assays are needed to assess the repertoire of functional MANA-specific T cells in oncology. Assays analyzing in vitro cytokine production such as ELISpot and intracellular cytokine staining have been useful but have limited sensitivity in assessing tumor-specific T-cell responses and do not analyze antigen-specific T-cell repertoires. The FEST (Functional Expansion of Specific T cells) assay described herein integrates T-cell receptor sequencing of short-term, peptide-stimulated cultures with a bioinformatic platform to identify antigen-specific clonotypic amplifications. This assay can be adapted for all types of antigens, including MANAs via tumor exome-guided prediction of MANAs. Following in vitro identification by the MANAFEST assay, the MANA-specific CDR3 sequence can be used as a molecular barcode to detect and monitor the dynamics of these clonotypes in blood, tumor, and normal tissue of patients receiving immunotherapy. MANAFEST is compatible with high-throughput routine clinical and lab practices.

UR - http://www.scopus.com/inward/record.url?scp=85051390255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051390255&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-18-0129

DO - 10.1158/2326-6066.CIR-18-0129

M3 - Article

C2 - 29895573

AN - SCOPUS:85051390255

VL - 6

SP - 888

EP - 899

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 8

ER -